Study S001128

A Randomized, 4-Period Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01021527
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: SINGLE
Status: COMPLETED
Enrollment: 12
Start: 2008-02
Primary completion: 2008-03
Lead sponsor: Merck Sharp & Dohme LLC
Conditions: Healthy
Interventions: OTHER:Comparator: Treatment A; DRUG:Comparator: Treatment B; DRUG:Comparator: Treatment C; PROCEDURE:Comparator: graded glucose infusion
Results posted: FALSE
Secondary identifiers: OTHER:099; OTHER:2009_697

Registered primary outcomes

beta-cell glucose sensitivity (slope of the relationship between insulin secretion rate and glucose) [0-160 minutes after start of infusion]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.